ESTRO 35 Programme book

Debate THIS HOUSE BELIEVES THAT PROGRESS IN THE TREATMENT OF LOCALLY ADVANCED NSCLCWILL COME FROM: 14:30 - 15:45 | AUDITORIUM The prognosis of locally advanced NSCLC remains poor with the majority of patients failing locally and/or distantly. Evidence supports that improved local tumour control improves survival and this can be improved by the use of advanced radiotherapy techniques and altered fractionation. In the field of systemic treatment, immune checkpoint inhibition and targeted agents, which have changed the treat- ment paradigm in advanced NSCLC, are being evaluated in locally advanced disease. The speakers will debate which of the two treatment modalities is the most likely to have a significant impact on the

SATURDAY 30 APRIL 2016

outcome of this group of patients. Chair: C. Faivre-Finn (UK) Chair: P. Van Houtte (Belgium)

14:30 > Radiation treatment intensification Speaker: J. Belderbos (The Netherlands)

SP-0102

14:50 > Better systemic therapy

Speaker: J. Van Meerbeeck (Belgium)

SP-0103

15:10 > Rebuttal

Speaker: J Belderbos (The Netherlands)

15:20 > Rebuttal

Speaker: J. Van Meerbeeck (Belgium)

15:30 > Discussion

Symposium ACTIVE SURVEILLANCE FOR LOWRISK PROSTATE CANCER: TO TREAT OR NOT TO TREAT? 14:30 - 15:45 | GIALLA Chair: A. Bossi (France) Co-chair: C. Cozzarini (Italy)

14:30 > Does (very) low risk prostate cancer really exist? Speaker: F. Algaba (Spain)

SP-0104

14:55 > The role of MRI in active surveillance Speaker: G. Villeirs (Belgium)

SP-0105

15:20 > Active surveillance: challenges and perspectives. The clinician point of view Speaker: R. Valdagni (Italy)

SP-0106

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

74